Abstract
Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Volume: 7 Issue: 3
Author(s): Wim J. Oyen, E. J. Postema, Frans H. Corstens, Otto C. Boerman and Manuel J. Koppe
Affiliation:
Keywords: renal cell cancer, colorectal cancer, G250, CD20, carcinoembryonic antigen, Non-Hodgkin's lymphoma, radionuclide, monoclonal antibodies, Radioimmunotherapy
Abstract: Radioimmunotherapy (RIT) using radiolabeled monoclonal antibodies (MAbs) directed against tumor-associated antigens has evolved from an appealing concept to one of the standard treatment options for patients with non-Hodgkins lymphoma (NHL). Inefficient localization of radiolabeled MAbs to nonhematological cancers due to various tumor-related factors, however, limits the therapeutic efficacy of RIT in solid tumors. Still, small volume or minimal residual disease has been recognized as a potentially suitable target for radiolabeled antibodies. Several strategies are being explored aimed at improving the targeting of radiolabeled MAbs to solid tumors thus improving their therapeutic efficacy. In this review, various aspects of the application of radiolabeled MAbs as anti-cancer agents are discussed, and the clinical results of RIT in patients with hematological and various solid cancers (colorectal, ovarian, breast and renal carcinomas) are reviewed.
Export Options
About this article
Cite this article as:
Oyen J. Wim, Postema J. E., Corstens H. Frans, Boerman C. Otto and Koppe J. Manuel, Radionuclide Therapy of Cancer with Radiolabeled Antibodies, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/187152007780618126
DOI https://dx.doi.org/10.2174/187152007780618126 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ustekinumab-induced Sarcoidosis in a Patient with Psoriatic Arthritis
Current Drug Safety Synthesis and Anti-tumor Activities of Novel Phenyl Substituted Suberoylanilide Hydroxamic Acid Derivatives Against Human Cancer Cells
Medicinal Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Apoptosis Suppression by Candidate Oncogene PLAC8 is Reversed in Other Cell Types
Current Cancer Drug Targets Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology The Challenges Involved in Modeling Toxicity Data In Silico: A Review
Current Pharmaceutical Design Interaction Between Arsenic Trioxide and Human Primary Cells: Emphasis on Human Cells of Myeloid Origin
Inflammation & Allergy - Drug Targets (Discontinued) Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Clinical Applications of <sup>18</sup>F-FDG PET/CT in Monitoring Anti-cancer Therapies
Current Pharmaceutical Biotechnology Chemical Properties and Mechanisms Determining the Anti-Cancer Action of Garlic-Derived Organic Sulfur Compounds
Anti-Cancer Agents in Medicinal Chemistry TEM8 Targeted Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Functional Analyses of the Human Genome Based on Large-Scale Fulllength cDNA Resources
Current Genomics Isolation, Purification, Characterisation and Application of L-ASNase: A Review
Recent Patents on Biotechnology The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology
Current Medicinal Chemistry Carbohydrates: Potential Sweet Tools Against Cancer
Current Medicinal Chemistry Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity
Current Medicinal Chemistry